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A Frameshift Variant in the CHST9
Gene Identified by Family-Based
Whole Genome Sequencing Is
Associated with Schizophrenia in
Chinese Population
Jingchun Chen1, Jain-Shing Wu1, Travis Mize1,2, Marvi Moreno1, Mahtab Hamid1,
Francisco Servin1, Bita Bashy1, Zhongming Zhao3,4, Peilin Jia3, Ming T. Tsuang5,
Kenneth S. Kendler6, Momiao Xiong7 & Xiangning Chen8
Recent studies imply that rare variants contribute to the risk of schizophrenia, however, the exact
variants or genes responsible for this condition are largely unknown. In this study, we conducted whole
genome sequencing (WGS) of 20 Chinese families. Each family consisted of at least two affected siblings
diagnosed with schizophrenia and at least one unaffected sibling. We examined functional variants
that were found in affected sibling(s) but not in unaffected sibling(s) within a family. Matching this
criterion, a frameshift heterozygous deletion of CA (–/CA) at chromosome 18:24722722, also referred
to as rs752084147, in the Carbohydrate Sulfotransferase 9 (CHST9) gene, was detected in two families.
This deletion was confirmed by PCR-based Sanger sequencing. With the observed frequency of 0.00076
in Han Chinese population, we performed both case-control and family-based analyses to evaluate its
association with schizophrenia. In the case-control analyses, Chi-square test P-value was 6.80e-12 and
the P-value was 0.0008 after one million simulations. In family-based segregation analyses, segregation
P-value was 7.72e-7 and simulated P-value was 5.70e-6. For both the case-control and family-based
analyses, the CA deletion was significantly associated with schizophrenia in the Chinese population.
Further investigation of this gene is warranted in the development of schizophrenia by utilizing larger
and more ethnically diverse samples.
Schizophrenia is a complex psychiatric disorder with high heritability and complex genetic architecture1. To
elucidate the etiology of this disease, much emphasis has been placed on the detection of common risk variants
through genome-wide association studies (GWASs). To date, more than 100 loci have been found to be significantly associated with schizophrenia2. However, common variants such as single nucleotide polymorphisms
(SNPs) are unable to account for all of the heritability. In fact, the variants identified by GWASs only provide an
estimated heritability of approximately 7%3, suggesting there is still large missing heritability to be discovered.
In addition, most of the individual genes from these common SNPs do not convey a direct risk for the disease.
On the other hand, there is evidence that rare variants, such as rare SNPs with minor allele frequency (MAF) less
than 0.01 and copy number variations (CNVs), have substantially larger effects on schizophrenia1. It is believed
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Table 1. Whole genome sequencing summary statistics. Abbreviations: GB: gigabyte; SD: standard deviation;
SNP: single nucleotides polymorphism; InDel: insertion and deletion; SV: structural variant.

that genes from those rare variants often confer a clear risk to the disease, which may potentially lead to the identification of novel treatment targets. With the advancements of genomic technology, whole genome sequencing
(WGS) is widely accessible and has become the most invaluable tool for identifying rare SNPs and CNVs in complex diseases, such as schizophrenia. This approach is especially powerful to detect rare variants in family-based
studies with cases cluster over unrelated case-control studies, where disease-causing rare variants may be seen
only once or twice among tens of thousands of subjects4, though such family samples might be difficult to collect.
In this family-designed study, we applied WGS to 20 Chinese families, each of which consisted of at least two
affected siblings, one unaffected sibling, and one parent. In the initial analyses, we were only interested in functional variants, such as frameshift mutation, that were found in the affected sibling(s) but not in the unaffected
sibling(s) in a family. The variants meeting this criterion were then matched across families.
Seven frameshift mutations were found to meet the specified criteria. Among them, a variant at CHST9 was
first selected to further investigate due to its previously reported association with schizophrenia via CNVs5. We
reported here that a novel frameshift deletion (–/CA, heterozygous) from CHST9 gene was detected at chromosome 18:24722722 based on gnomAD database (http://gnomade.broadinstitute.org) (dbSNP ID: rs752084147,
c.50_51delTG, p.Val17AlafsTer19). We observed this deletion in three children with schizophrenia from two
independent families; none of the unaffected children were found to have the deletion. One parent from one of
the two families, not diagnosed with schizophrenia but with another mental illness, also had this deletion. The
deletion was confirmed by PCR-based Sanger sequencing in all four subjects. Statistical analyses from both the
case-control and family-based analyses indicated that the CA deletion from CHST9 gene was significantly associated with schizophrenia in the Chinese population.

Results

Whole genome sequencing summary. Summary statistics of the WGS were listed in Table 1. The median

depth of sequencing was 35.34 x and the median coverage was 99.69%, meeting the target sequencing depth of
30 x. On average, each subject had > 680 million reads, 3.1 million SNPs, 430,000 indels, and 579,000 structural
variants (SVs).

Family kinship analysis and aneuploidy analysis.

The centered IBS method6 was followed to verify
family relationship using 250,000 variants shared between the 101 subjects sequenced in this study. Aneuploidy
analysis was also conducted utilizing the BCFtools package to confirm the gender of each individual7. In the
family kinship analysis, two subjects (02C11277 and 01C05768) were removed from further examination as they
were found to be unrelated to any of the other 99 subjects in this study (see Supplementary Table S1). One affected
subject (01C07598) was originally assigned to Family 35-02497 but actually belonged to Family 35-39622, leaving
Family 35-02497 with only one affected and one unaffected subject. Subject 01C08839 with missing age was listed
as the mother of Family 35-4560, however, kinship analysis indicated that she was more likely to be the daughter
of this family. Referring back to the original family data, indeed, the family had a 47-year-old daughter who was
never diagnosed with a psychiatric illness. 01C08839 was, therefore, assigned as an unaffected daughter in this
family. For all other subjects, family relationships were confirmed by kinship analysis. The sex of all subjects was
also confirmed with the prediction from BCFtools package. The kinship matrix was listed in Supplementary
Table S1, and the sample description and results from sex prediction were listed in Supplementary Table S2.

Frameshift mutations and CHST9 deletion. Using the strategies described in the Selection of potential risk variants under Materials and Methods, we generated a variant list that included the variants only present in affected sibling(s), but not in the unaffected sibling(s). Parents were excluded from the initial analyses.
Supplementary Table S3 showed the number of functional annotations before and after filtering. Only 27.37%
of total variants and 19.66% of variants from exons remained after filtering. Frameshift insertions and deletions
(indels) are coding variants that cause amino acid changes from the variant site onward. This type of variant
was the primary target of this study due to the likely functional alteration of their coded proteins. In total, seven
frameshift indels were identified in two or more families (Table 2). Among these variants, the two-base-pair
deletion at chr18:24722722 in the CHST9 gene was of special interest as it was the only gene reported to be associated with schizophrenia in a previous study5. In that report, a CNV of CHST9 was found to be associated with
schizophrenia. From a gene dosage perspective, loss-of-function (LoF) from a frameshift deletion could have
similar effects as to those resulting from a loss of copy number. To further assess whether or not this mutation was
de novo, the binary sequence alignment map (BAM) files were visually inspected using the IGV software (http://
software.broadinstitute.org/software/igv/)8,9. All 99 subjects were examined at this location, including the parents.
With the IGV analysis, the father of Family 35-13523, who had an affected son with this deletion, was also found
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6
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3

p.Pro453AlafsTer54

sulfotransferase

7
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deletion

18

24722722
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GCA/G

0.00020

2

p.Val17AlafsTer19

schizophrenia

Table 2. Frameshift mutations observed in two or more families. Abbreviations: Chr: chromosome; Fam#:
numbers of family detected; MAF: minor allele frequency.

Figure 1. A flow chart of the WGS analysis study.
to have the same deletion (Fig. 2). Although the father was not diagnosed with schizophrenia, he was diagnosed
with a non-specified mental illness (Table S2). The mother, who was never diagnosed with any psychiatric illness,
did not have the deletion at this locus. As this deletion was found in the father of Family 35-13523, the variant
was excluded as a de novo mutation. In Family 35-02478, two affected children, one son and one daughter, had
the deletion, while the father, who was never given a diagnosis of any psychiatric illness, did not have the deletion. No clinical data or DNA was available for the mother of this family. Due to the extremely low probability of
having the exact same de novo mutation occur twice within two independent families in a single generation, it
was concluded that the mutation was likely inherited from the mother. In total, our WGS analysis identified four
subjects that had the heterozygous frameshift deletion (–/CA) in the CHST9 gene. Of these four individuals, three
were affected children with schizophrenia from two independent families, and one was a parent diagnosed with
a mental illness other than schizophrenia. Our results indicated that not all of the affected children from these two
families had this mutation, implying that other genetic, or environmental factors might also play a significant role
in the development of this disease. It should be noted that the CHST15 gene was also considered a potential target
as it belongs to the same family as the CHST9 gene. The variant in CHST15 contained 13 or more homopolymeric
G region, which made the call of exact variants difficult from Sanger sequencing. More time is required to follow
up with this gene. Among the other genes listed in Table 2, their functions were largely unknown, except that
SHCBP1L (SHC binding and spindle associated 1 like), a gene that has been reported to play an important role in
spermatogenesis in mammals10.
As shown in Supplementary Tables S4 and S5, other variants, such as stop-loss and stop-gain, were also summarized as they might also dramatically change the protein functions. Among these variants, 15 genes were
reported to be associated with schizophrenia. These variants are potential targets for future investigations.

Sanger sequencing verification of the CHST9 deletion.

PCR-based Sanger sequencing was used to
confirm the CHST9 mutation as described in Materials and Methods. All members from Family 35-13523 and
Family 35-02478 were subjected to verification. The four subjects found to have the CA deletion from WGS
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Figure 2. Pedigrees of Family 35-02478 and Family 35-13523. Circles and squares denote females and males,
respectively. A black box represents an affected subject. A cross inside the shape denotes that the individual was
not diagnosed with schizophrenia but with another mental illness. An arrow indicates the proband of the family.
A question mark represents that the individual’s DNA was unavailable. A red circle outside the shape means the
individual had the two base pair CA frameshift deletion in the CHST9 gene.

analysis were all confirmed with Sanger sequencing. Therefore, the results of Sanger sequencing were 100% concordant with the results of WGS. Figure 3A shows a representative chromatography of Sanger sequencing for a
normal sequence and a heterozygous CA deletion sequence.

Association analysis of CA deletion in CHST9 with schizophrenia in the Chinese population. In
this study, we conducted WGS with a family design in 20 Chinese families. For association analyses, two different approaches were conducted in this study. One approach was based on a case-control assumption where the
affected individuals or risk allele carriers were considered as cases and compared to the general Han Chinese
population. Here we conducted a Chi-square test with Yates’ Correction to compare the frequency of potential
risk variants with the MAF from large exome and genome sequence databases, such as the Genome Aggregation
Database ([GnomAd], http://gnomad.broadinstitute.org/)11, Exome Aggregation Consortium ([ExAC], http://
exac.broadinstitute.org/)11, and the Chinese Gene Mutation Database [CNGMD v.5.0] (http://cngmd.virgilbio.
com/). As different databases had reported different MAF for this deletion, we believed that the general Han
Chinese population from CNGMD v.5.0 database was the best reference for our Han Chinese families. We considered that the subjects in our WGS study were either high-risk carriers (parents) or cases (children with schizophrenia), whereas the subjects from these databases were general population controls. Under this assumption, we
conducted a Chi-square test with Yates’ Correction. Given the frequency of 0.00076 in the general Han Chinese
from CNGMD v.5.0 database, the results showed that there was a significant association between this deletion and
schizophrenia in the Chinese population (P = 2.15e-6 for the carrier group, and P = 6.80e-12 for the case group).
Since the CA deletion was a rare variant, we further conducted simulations to evaluate its association with schizophrenia. We used the simulation function as implemented in the MonteCarlo R package and performed 1 million
simulations for the Chi-square test for the high-risk carrier and case groups separately. The results remained
significant (P-values were 0.0032 and 0.0008, respectively for the carrier and case groups). In addition, we also
conducted the association tests using the MAF information from the larger databases (gnomAD and ExAC) as
references. The association P-values for the carrier and case groups varied from 0.0046 to 1.90e-75. More details
of the results were shown in Table 3.
Another approach was family-based association analyses. In these analyses, we used the gene-based segregation method (GESE)12 that assumed Mendelian segregation and 100% penetrance. With the observed frequency
of 0.00076 in Han Chinese population, we first estimated the segregation probabilities for the two families (Family
35-13523, P-value = 0.0012 and Family 35-02478, P-value = 0.0006, respectively), and then obtained the joint segregation probability for the two families (P-value = 7.72e-7). With 10,000,000 simulations, the joint segregation
probability was 5.70e-6.
Overall, both the Chi-square and family segregation test from the family-designed study on the 20 Chinese
families indicated that the frameshift CA deletion was significantly associated with schizophrenia in the Chinese
population.

Discussion

In this study, we attempted to identify rare variants/genes associated with schizophrenia in the Chinese population using a family-based WGS approach. We found a two-base-pair CA deletion in the CHST9 gene in three
schizophrenia cases from two independent families. One parent, who was not diagnosed with schizophrenia, but
had another mental illness, was also found to have this deletion. Two different approaches were used to evaluate
the association of this deletion with schizophrenia. In the case-control approach, Chi-square tests with Yates’s correction and permutation showed a significant association between the CA deletion and schizophrenia. In the scenario where schizophrenia patients were compared to the reference population, the P-values were 6.80e-12 and
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Scenario 1
Database
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ExAC

CNGMD
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Allele#

Allele freq Chiq.P-Val

SIM.P-Val

Chiq.P-Val

East Asian

49

19476

2.52E-03

4.56E-03

0.01827

1.52E-05

SIM.P-Val
0.00489

South Asian

3

30210

9.93E-05

2.16E-38

0.00005

1.90E-75

0.00002

overall

54

279362

1.93E-04

9.72E-32

0.00012

2.32E-62

0.00004

East Asian

23

8626

2.67E-03

7.67E-03

0.02219

4.29E-05

0.00593

South Asian

2

16510

1.21E-04

1.15E-26

0.00013

4.98E-52

0.00004

overall

25

120728

2.07E-04

1.42E-28

0.00018

4.87E-56

0.00004

Han_Chi(CHH, CHS, CHB) 4

5254

7.61E-04

2.15E-06

0.00321

6.80E-12

0.00080

overall

7352

1.50E-03

2.54E-04

0.00823

6.31E-08

0.00213

11

Table 3. Association analyses of the CA deletion with various populations as references. Abbreviations:
Chiq.P-Val: P-value from Chi-squared test; CNGMD: Chinese Gene Mutation Database; ExAC: The Exome
Aggregation Consortium; Freq.: frequency; gnomAD: Genome Aggregation Database. Han_Chi: all Han
Chinese in the CNGMD database, including CHH (Han Chinese in China), CHS (Han Chinese in the South
of China), and CHB (Han Chinese in Beijing). SIM.P-Val: P-value computed by Monte Carlo simulation when
setting the number of replicates B = 1,000,000.

0.0008 for Chi-square and permutation tests, respectively. We made an arguement that this scenario was more
appropriate as we were directly comparing schizophrenia cases to the healthy general population. Even in the scenario where we treated the parents as high-risk carriers, we found that the CA deletion was still significantly associated with schizophrenia (P-values were 2.15e-6 and 0.0032 for Chi-square and permutation tests, respectively).
With the family-based segregation analyses (GESE), the joint segregation P-value for the two families was 7.72e-7.
Simulated P-value for the segregation was 5.70e-6. Under the assumption of Mendelian segregation and 100%
penetrance, the GESE12,13 could be used to jointly evaluate multiple mutations in a single gene for association
with the disease of interest, given the observed frequencies in the general population. Although schizophrenia is
a complex disorder with incomplete penetrance, the segregation analyses are still appropriate. Overall, in either
the case-control or segregation analyses, we found that the CA deletion in CHST9 gene from our family study was
associated with schizophrenia in the Chinese population. However, the study does have some limitations: (1) The
sample size in this study is relatively small. Despite that we have observed the association, further studies with
larger samples are need to validate our results. (2) Our study only includes those from the Chinese population.
Incorporating different ethnic groups may provide more insights for its association with the disease.
Carbohydrate sulfotransferase 9 (CHST9) gene (HGNC ID: 19898; Entrez Gene: 83539; Ensembl:
ENSG00000154080; OMIM: 610191), located on human chr18q11.22 (genomic location: chr18: 24495595–
24765302, reference genome GRCh37/hg19), contains five exons with a total gene length of about 270 kb. The
cDNA encodes a type II membrane protein with 443 amino acids (AA) that belong to the sulfotransferase 2 family. This protein is localized to the Golgi membrane and is thought to catalyze the transfer of sulfate to position
four of the non-reducing N-acetylgalactosamine (GalNAc) residues in both N-glycans and O-glycans14,15. Thus,
it is also referred to as GALNAC4ST-2 or GALNAC-4-ST2. In humans, it is highly expressed in the trachea, but
is also expressed in the brain, particularly in the hippocampus and hypothalamus16. The sulfate groups on carbohydrates confer highly specific functions to glycoproteins, glycolipids, and proteoglycans17 that are critical for
cell-cell interaction, signal transduction, and embryonic development18.
As shown in Fig. 3B, the CHST9 protein contains a 12-AA cytoplasmic domain, a 21-AA transmembrane
domain (TM), and a 410-AA luminal domain19. Evidence has shown that the luminal domain of the protein
contains four potential N-linked glycosylation sites and two motifs: putative 5′-phosphosulfate-binding site
(5′-PSB) and 3′-phosphate-binding site (3′-PB) of 3′-phosphoadenosine-5′-phosphosulfate (PAPS)19. The first
two domains play an important role in substrate recognition, whereas the last domain holds the sulfotransferase
that mainly catalyzes the transfer of sulfate as mentioned above. The TM domain also plays essential roles in
anchoring and stabilizing the protein to the membrane.
The two-base-pair frameshift deletion of CA at chr18:24722722 is located in the first exon of the CHST9 gene.
This variant, a c.50_51delTG based on NM_031422.5, is predicted to result in a truncated protein (p.Val17AlafsTer19) that consists of only 34 AA. More importantly, the mutation starts at the 17th AA in the TM domain,
where Valine (Val) was substituted with Alanine (Ala) followed by an additional 17 new residues. The protein
sequence changes derived from the CA deletion suggest that the truncated protein is highly likely to lose the
major functions of the protein, including recognizing the substrates, anchoring the protein to the membrane,
and transferring a sulfate group to other proteins. As such, this variant should be classified as an LoF mutation, a
category that includes nonsense, frameshift, splicing acceptor, and splicing donor variants. It is possible that the
loss of function of the CHST9 protein may interfere with normal brain development, and thus contribute to the
development of schizophrenia. More specifically, the loss of the chondroitin 4-sulphotransferase activity might be
critical in the process of disease development. Indeed, studies have shown that well-organized perisynaptic aggregates, known as perineuronal nets (PNNs), were formed by the extracellular matrix (ECM), where chondroitin
sulfate proteoglycans (CSPGs) are the primary components20–24. Studies have also indicated that PNNs play a
critical role in neural patterning, synaptic signaling, plasticity and neuroprotection during postnatal development
and adulthood. Therefore, the LoF mutation in CHST9 may change the normal structures and functions in CSPGs
or PNNs. As a result, it may interfere with brain development and cause neural malfunction and diseases, such as
schizophrenia and other psychiatric disorders25–29. In addition, evidence also showed that the formation of these
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Figure 3. Sanger sequencing of normal and affected individuals, and structure of the human CHST9 gene and
coded protein. (A) Sanger sequencing of normal and affected individuals. The –/CA variant identified was
verified via Sanger sequencing. Sequence from an unaffected child was clean and matched to the sequence
from the human genome browser GRCH37/hg19. The sequence with the heterozygous deletion from an
affected child showed double peaks immediately after the CA deletion. The red arrow indicated the locus of
deletion. (B) Structure of the human CHST9 gene and coded protein. Upper panel shows the five exons that
are transcribed into the coding sequence (black boxes) from the 5′ to 3′ direction. Exons are numbered from
1 (E1) to 5 (E5). Bottom panel, the translated CHST9 protein is shown. TM denotes the transmembrane
domain. Putative binding sites for the 5′-phosphosulfonate group (5′-PSB) and 3′-phosphate group (3′-PB) of
3′-phosphoadenosine-5′-phosphosulfate (PAPS) are marked. Truncated protein caused by the deletion in this
study is indicated in red.

specialized ECM aggregates was associated with distinct populations of GABAergic interneurons and that CSPG
abnormalities were found in several brain regions of patients with schizophrenia29. Interestingly, we identified
another variant at rs200905582 (chr10:125780762) in CHST15 gene (Table 2), which also belongs to a gene family
encoding membrane-bound sulfotransferases as CHST9 gene does30. This result suggested that proteins with
sulfotransferases might be important in schizophrenia. Further studies on these proteins, gene-set or pathway
analysis might provide more insights to understand the pathophysiological roles in human diseases.
Direct evidence for the functional impact of CHST9 has not been reported thus far. In the literature, there was
one report that schizophrenia was associated with CNV of CHST931, where patients exhibited a slight increase in
genome doses of CHST9. A similar result was also reported for autism32. In this study, the CA deletion of CHST9
gene is significantly associated with the diagnosis of schizophrenia. The bioinformatic analysis further suggests
that the truncated protein caused by the CA deletion of this gene would lose its major function as a sulfate transferase. As it currently stands, it is unclear how this gene may contribute to schizophrenia.
In addition to psychiatric disorders, CHST9 CNVs were also found to be associated with acute myelogenous
leukemia (AML)33, as well as other types of hematologic malignancies34, suggesting that CHST9 may play a role
in the development of hematologic malignancies. CHST9 has also been linked to the development of breast cancer35,36 and gastric cancer37. Further examination of this gene is warranted to better understand the function
of this gene, as well as the genetic basis and molecular pathogenesis of schizophrenia and other diseases. More
thorough functional studies on this gene may lead to a novel target for the treatment of these disorders, especially schizophrenia for Chinese patients.

Materials and Methods
Subjects.

The subjects of a single ethnicity (Taiwanese Han Chinese) were recruited in the Taiwan
Schizophrenia Linkage Study (TSLS) from 1998 to 2002. Detailed information has been described previously38,39.
Briefly, families with at least three siblings, two of whom were diagnosed with schizophrenia, were recruited. All
enlisted subjects were interviewed using the Diagnostic Interview for Genetic Studies (DIGS)40, accompanied by
the Family Diagnostic Interview for Genetic Studies (FIGS) (https://www.nimhgenetics.org/interviews/figs/). The
final diagnostic assessment was based on the criteria of the fourth edition of the Diagnostic and Statistical Manual
(DSM-IV), joined with the record of DIGS, FIGS, interviewer notes, and hospital anamnesis. Whole blood
samples were collected and sent to the National Institute of Mental Health (NIMH) Repository and Genomics
Resource (RGR) to be transformed into lymphoblastoid cell lines and stored. DNA samples extracted from the
cell lines were used for WGS. Twenty Chinese families (total of 101 subjects) were selected from the TSLS. The
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selection criteria were that each family had (1) at least two affected siblings, (2) at least one unaffected sibling at
the age of 32 or older, and (3) at least one of the parents. Of these 20 families, eight had both parents, whereas
the remaining 12 had only one parent. Two subjects were excluded after kinship analysis6, as they did not belong
to any of the 20 families, resulting in 99 subjects for the final analysis. Informed consent was obtained from all
participants and/or their legal guardians for the original study and the study reported herein was approved by
the Institutional Review Board at Virginia Commonwealth University as it was initially started there, and then
transferred to University of Nevada, Las Vegas. All methods were performed in accordance with the relevant
guidelines and regulations.

WGS, variant calling, and annotation. WGS was carried out on the Illumina HiSeq. 2000 platform using

paired-end chemistry with 75 base-pair read length through NovoGene (Beijing, China). NovoGene conducted
first-round quality control, removed adapter sequences, and pruned low-quality reads. Once the FASTQ files
were received from NovoGene, the Genome Analysis Toolkit (GATK, version 3.7) best practices pipeline41–43 was
followed to process the sequence reads (see Fig. 1 and Supplementary Descriptions S6). Briefly, any remaining
Illumina adapter sequences were removed via Picard, and reads were aligned utilizing the Burrows-Wheeler
Aligner. Individual sample variants were called by the GATK HaplotypeCaller function, then joint genotyping was performed through the use of GATK’s GenotypeGVCFs to produce a multi-sample variant call format
(VCF) file. GRCh37/hg19 was used as the human reference genome. Second-round quality filtering, such as
removing residual low-quality reads, base quality score recalibration, and variant quality score recalibration were
accounted for in the various preprocessing tools of GATK’s best practices pipeline. All VCF files were annotated
with ANNOVAR44 to extract functional annotation and GATK’s VariantAnnotator to extract variant annotation. Interactive Genome Viewer (IGV) (http://software.broadinstitute.org/software/igv/)8,9 was used to visually
inspect the called variants. The whole genome sequencing project PRJNA551447 generated during the current
study in the format of fastq files have been deposited at the National Center for Biotechnology Information
(NCBI) repository.

Polymerase chain reaction (PCR)-based Sanger sequencing validation.

For the families where
candidate variants were found, DNA from all members of the family was subjected to PCR-based Sanger sequencing by capillary electrophoresis according to standard molecular biology practices (ABI 3130 genetic analyzer,
ThermoFisher Scientific). Primer3Plus45,46 was used to design the PCR primers. For the CHST9 deletion, the
forward primer sequence was 5′-AAGAAAAAGCACATGTGTTA-3′ and the reverse primer sequence was
5′-CAGATGGCTGCATTTCTCCT-3′. Reactions were performed on an Eppendorf MasterCycler (Eppendorf
North America, New York, USA) under the following cycling conditions: denaturation at 95 °C for 2 min, 30
cycles of 95 °C for 15 sec, 55 °C for 30 sec, 72 °C 30 sec, and an extension with 72 °C for 5 min. Sanger sequencing
data was then analyzed using Chromas software47 (https://seqcore.brcf.med.umich.edu/sites/default/files/html/
interpret.html).

Selection of potential risk variants. Potential risk variant discovery was performed utilizing the following procedure. First, all variants that were found to only occur in affected sibling(s), but not in the unaffected
sibling(s), within a single family, were retained while all other variants were removed. The retained variants were
considered to have the potential to be associated with the disease within a family. Second, these variants were then
matched across families. Variants found in two or more families were selected as candidates for further analyses.
Third, variants were classified based on their genomic functions, such as exonic, intronic, etc. In this analysis,
coding variants that resulted in a change of amino acid, i.e. non-synonymous SNPs, and frameshift insertions and
deletions (indels), were the primary focus. Fourth, Sanger sequencing was used to verify the frameshift mutations.
Fifth, association analyses were conducted using a Chi-square test with Yates’ correction and Monte Carlo simulation test. Verified potential risk variants were compared to the MAF from large exome and genome sequence
databases (See details in Section of Satatistical analyses). We proposed that the subjects in our WGS study were
either high-risk carriers (parents) or cases (children with schizophrenia), whereas the subjects from these databases were general population controls.
Statistical analyses.

Two approaches were used in this study. The first was a case-control approach where
the Chi-square test was used. We used the R function chisq.test to conduct a Pearson’s Chi-square test with
Yates’ Correction and Monte Carlo simulation test48. This test calculated the difference of the allele frequencies
between the cases (subjects with schizophrenia) or carriers (parents of cases) and controls (general population
from databases, such as gnomAD, ExAC, and CNGMD v.5.0, as mentioned above). The frequency of the variant
at rs752084147 varies among different databases from different populations. According to the initial study, all of
the 20 Taiwan families belong to Han Chinese population38,39, therefore, the general Han Chinese from CNGMD
v.5.0 database were deemed to be the best reference as the control. In the CNGMD v.5.0 database, the deletion
frequency of rs752084147 in the Han Chinese population was 0.00076 (4 alleles from 5254 alleles). We used this
frequency as the reference for control in the latter Chi-square test. Here, although each family had 2 or more
affected individuals, we only counted as one case in each family. This was because these siblings were related;
variants shared between the affected siblings were likely transmitted from the same parent. Based on our study
design, two scenarios were considered to assess the frequency of the CA deletion in the 20 families. Scenario 1:
Considering the parents of these 20 families as a high-risk population (carriers), we compared their allele counts
with the general Han Chinese population. Under this condition, there was a total of 80 effective alleles in the 40
potential carriers (20 families, each contributed 4 alleles). Therefore, allele counts from the carrier group were
counted 2 alleles with CA deletion among total 80 alleles. Scenario 2: Considering the affected subjects of the 20
families as cases, we compared their allele counts with the general Han Chinese population. In Scenario 2, we
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could count a total of 40 effective alleles in the 20 cases (20 families, each family contributed 2 alleles). Again,
we only counted one case in each family for the reason mentioned above. Therefore, allele counts from the case
group were 2 alleles with CA deletion among total 40 alleles. Scenario 2 was a direct comparison between case and
control, thus, we believed it was more appropriate.
The second approach was a family-based segregation analysis. Here we used the R package of Gene-based
Segregation Test (GESE) method reported by Qiao et al.12,13 under the assumption of Mendelian segregation and
100% penetrance. In this method, multiple mutations in a single gene could be jointly evaluated for association
with the disease of interest given the observed frequencies in the general population. The segregation analyses
are also appropriate even though schizophrenia is a complex disorder with incomplete penetrance. Therefore, we
used it to estimate the segregation probability for the families given the CA deletion frequency observed in the
Han Chinese population, and used simulations to assess the association with schizophrenia.

Data Availability

The whole genome sequencing project PRJNA551447 generated during the current study in the format of fastq
files have been deposited at the National Center for Biotechnology Information (NCBI) repository (https://dataview.ncbi.nlm.nih.gov/object/PRJNA551447?reviewer=sorlv9h1kc2d2sa358m70br0pu). All the datasets will be
available on 2019-08-12 or upon publication, whichever is first.
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